Fortress Biotech, Inc. (FBIO) Analysts See $-0.57 EPS

February 15, 2018 - By Michael Collier

 Fortress Biotech, Inc. (FBIO) Analysts See $ 0.57 EPS

Analysts expect Fortress Biotech, Inc. (NASDAQ:FBIO) to report $-0.57 EPS on March, 15.They anticipate $0.14 EPS change or 32.56 % from last quarter’s $-0.43 EPS. After having $-0.67 EPS previously, Fortress Biotech, Inc.’s analysts see -14.93 % EPS growth. The stock increased 0.85% or $0.03 during the last trading session, reaching $3.55. About 171,606 shares traded or 48.44% up from the average. Fortress Biotech, Inc. (NASDAQ:FBIO) has risen 52.16% since February 15, 2017 and is uptrending. It has outperformed by 35.46% the S&P500.

Fortress Biotech, Inc. (NASDAQ:FBIO) Ratings Coverage

Among 2 analysts covering Fortress Biotech (NASDAQ:FBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fortress Biotech had 7 analyst reports since July 11, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, December 12 by H.C. Wainwright. As per Wednesday, September 27, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, January 2 report. H.C. Wainwright maintained the shares of FBIO in report on Tuesday, December 5 with “Buy” rating. The company was maintained on Tuesday, July 11 by H.C. Wainwright. As per Thursday, August 10, the company rating was maintained by H.C. Wainwright.

Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company has market cap of $179.83 million. The firm offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It currently has negative earnings. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders.

More notable recent Fortress Biotech, Inc. (NASDAQ:FBIO) news were published by: which released: “Fortress Biotech to Present at the 2017 BIO International Convention” on March 09, 2017, also with their article: “Fortress Biotech Reports Second Quarter 2017 Financial Results and Recent …” published on August 09, 2017, published: “Fortress Biotech Announces Proposed Public Offering of Series A Preferred Stock” on November 01, 2017. More interesting news about Fortress Biotech, Inc. (NASDAQ:FBIO) were released by: and their article: “Fortress Biotech Completes Tender Offer for Shares of National Holdings …” published on September 12, 2016 as well as‘s news article titled: “Fortress Biotech Inc.” with publication date: December 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.